Seeing the light


The article 'Making Light Work' (Chemistry World, April 2012, p52) coincided with an alarming Daily Telegraph article relating the near-catastrophic increase in antibiotic resistance due to misuse by the NHS and in agriculture. It seems that big pharma is no longer interested in infection control for two reasons:

1 Any new antibiotic will quickly become ineffective due to acquired resistance.

2 They can make more money with continuous-use drugs to treat obesity, cholesterol and blood pressure than they can make on a 10-day course of antibiotics.

It is no great surprise that they are not interested in the potential of photodynamic therapy (PDT). The argument that they are not engineers is very negative, as in other fields of chemistry, such as cleaning and disinfection of food manufacturing equipment, it is routine for the chemical company to supply and service the dispensing equipment.

PDT is too good an opportunity to waste and there is a moral case for its commercialisation. I wonder if the experts in PDT would consider forming a cooperative organisation whereby professional scientists bought small shareholdings in the venture. I for one would be very happy to contribute a modest percentage of my pension.

M Barrett MRSC
Tewkesbury, UK


Related Content

Chemistry World podcast - October 2013

2 October 2013 Podcast | Monthly

news image

Chemists are helping palaeontologists discover the palette of fossil pigments, and helping toxicologists design greener compo...

Chemistry World podcast - February 2013

4 February 2013 Podcast | Monthly

news image

Graham Richards discusses crowdsourcing, Eric Wolff talks about ice cores and the team cover the latest chemical news

Most Read

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

The mothers of invention

24 February 2015 Managing Change

news image

Nina Notman profiles four researchers successfully balancing an academic career with family life

Most Commented

Sun rises on new solar route to hydrogen

27 February 2015 Research

news image

Photocatalyst has solar-to-hydrogen conversion efficiency of 2% and points way to cheap production of the gas

Hepatitis C drug patent challenged in Europe

19 February 2015 Business

news image

Campaign group says Gilead’s expensive blockbuster sofosbuvir is not innovative enough to warrant a patent